{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461088268
| IUPAC_name = 3-chloro-4-fluorophenyl-[4-fluoro-4-([(5-methylpyridin-2-yl)methylamino]methyl)piperidin-1-yl]methanone
| image = F-13640_structure.png
<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!--Identifiers-->
| index_label =
| index2_label =
| IUPHAR_ligand = 3925
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 208110-64-9
| ATC_prefix = none
| ATC_suffix =  
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 45305
| PubChem = 9865384
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RAT9OHA1YH
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8041076
| smiles = n2cc(C)ccc2CNCC(F)(CC3)CCN3C(=O)c(cc1Cl)ccc1F
| smiles2 = FC2(CCN(C(=O)c1ccc(F)c(Cl)c1)CC2)CNCc3ncc(cc3)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PKZXLMVXBZICTF-UHFFFAOYSA-N
<!--Chemical data-->
| C=20 | H=22 | Cl=1 | F=2 | N=3 | O=1
| molecular_weight = 393.857 g/mol
}}

'''Befiradol''' ('''F-13,640'''; '''NLX-112''') is a very [[potency (pharmacology)|potent]] and highly [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[full agonist]]. A SAR study revealed that replacement of the dihalophenyl moiety by 3-[[benzothiophene|benzothienyl]] increases maximal [[Efficacy#Pharmacology|efficacy]] from 84% to 124% (Ki=2.7 nM).<ref>{{cite journal | doi = 10.1021/jm100835q | pmid = 20860381 | volume=53 | issue=19 | title=Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists |date=October 2010 | journal=J. Med. Chem. | pages=7167–79 | vauthors=Bollinger S, Hübner H, Heinemann FW, Meyer K, Gmeiner P}}</ref> In recombinant cell lines expressing human [[5-HT1A receptor]]s, befiradol exhibits high agonist efficacy for a variety of signal transduction read-outs, including [[Extracellular signal–regulated kinases|ERK]] phosphorylation, [[G protein|G-protein]] activation, [[Receptor-mediated endocytosis|receptor internalization]] and [[adenylyl cyclase]] inhibition.<ref name=":0">{{Cite journal|last=Newman-Tancredi|first=Adrian|last2=Martel|first2=Jean-Claude|last3=Cosi|first3=Cristina|last4=Heusler|first4=Peter|last5=Lestienne|first5=Fabrice|last6=Varney|first6=Mark A.|last7=Cussac|first7=Didier|date=2017-06-14|title=Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist|url=https://www.ncbi.nlm.nih.gov/pubmed/28612503|journal=The Journal of Pharmacy and Pharmacology|volume=69|issue=9|pages=1178–1190|doi=10.1111/jphp.12762|issn=2042-7158|pmid=28612503}}</ref> In rat hippocampal membranes it preferentially activates [[G alpha subunit|GalphaO proteins]].<ref name=":0" /> In neurochemical experiments, befiradol activated 5-HT1A autoreceptors in rat dorsal Raphe nucleus as well as 5-HT1A heteroreceptors on pyramidal neurons in the frontal cortex.<ref>{{Cite journal|last=Lladó-Pelfort|first=Laia|last2=Assié|first2=Marie-Bernadette|last3=Newman-Tancredi|first3=Adrian|last4=Artigas|first4=Francesc|last5=Celada|first5=Pau|date=May 2012|title=In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat|url=https://www.ncbi.nlm.nih.gov/pubmed/22147258|journal=Psychopharmacology|volume=221|issue=2|pages=261–272|doi=10.1007/s00213-011-2569-9|issn=1432-2072|pmid=22147258}}</ref> It has powerful [[analgesic]] and [[antiallodynic]] effects comparable to those of high doses of [[opioid]] [[painkiller]]s, but with fewer and less prominent [[adverse effect|side effect]]s, as well as little or no development of [[Drug tolerance|tolerance]] with repeated use.<ref name="pmid12595749">{{cite journal |vauthors=Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC |title=Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain |journal=Pharmacology |volume=67 |issue=4 |pages=182–94 |date=April 2003 |pmid=12595749 |doi=10.1159/000068404 |url=}}</ref><ref name="pmid12694810">{{cite journal |vauthors=Bruins Slot LA, Koek W, Tarayre JP, Colpaert FC |title=Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640 |journal=European Journal of Pharmacology |volume=466 |issue=3 |pages=271–9 |date=April 2003 |pmid=12694810 |doi= 10.1016/S0014-2999(03)01566-8|url=}}</ref><ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-<nowiki/>{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16254131">{{cite journal |vauthors=Colpaert FC, Deseure K, Stinus L, Adriaensen H |title=High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=316 |issue=2 |pages=892–9 |date=February 2006 |pmid=16254131 |doi=10.1124/jpet.105.095109 |url=}}</ref><ref name="pmid17512927">{{cite journal |vauthors=Deseure K, Bréand S, Colpaert FC |title=Curative-like analgesia in a neuropathic pain model: parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist |journal=European Journal of Pharmacology |volume=568 |issue=1–3 |pages=134–41 |date=July 2007 |pmid=17512927 |doi=10.1016/j.ejphar.2007.04.022 |url=}}</ref>

Befiradol was discovered and developed by [[Pierre Fabre Group|Pierre Fabre Médicament]], a French pharmaceuticals company. In September 2013, befiradol was out-licensed to [[Neurolixis]], a California-based biotechnology company. [[Neurolixis]] announced that it intends to re-purpose befiradol for the treatment of [[Levodopa-induced dyskinesia]] in [[Parkinson's disease]].<ref>http://neurolixis.com/images/stories/nlx_pf_license_23sept13.pdf</ref> In support of this indication, [[Neurolixis]] received several research grants<ref>{{Cite web|url=https://www.michaeljfox.org/foundation/funded-grants.php?srch=Neurolixis&x=0&y=0&from=2000&to=&country=&institution=&researcher=|title=Parkinson's Disease Grants funded by the Michael J. Fox Foundation {{!}} Parkinson's Disease|website=The Michael J. Fox Foundation for Parkinson's Research {{!}} Parkinson's Disease|access-date=2017-06-23}}</ref> from the [[The Michael J. Fox Foundation|Michael J. Fox Foundation]] and preclinical data was published describing the activity of befiradol in animal models of [[Parkinson's disease]].<ref>{{cite journal| last1=Iderberg |first1=H |last2=McCreary |first2=AC |last3=Varney |first3=MA |last4=Kleven |first4=MS |last5=Koek |first5=W |last6=Bardin |first6=L |last7=Depoortère |first7=R |title=NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. | journal=Exp Neurol |date=September 2015 |volume=271 |pages=335–50 |pmid=26037043 | doi=10.1016/j.expneurol.2015.05.021 |url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26037043}}</ref><ref>{{cite journal| last1=McCreary |first1=AC |last2=Varney |first2=MA |last3=Newman-Tancredi |first3=A| title=The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements. | journal=Neuropharmacology | date=January 2016 | volume=105 | pages=651–60 | pmid=26777281 | doi=10.1016/j.neuropharm.2016.01.013 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26777281}}</ref>

== See also ==
* [[Eptapirone]]
* [[Flesinoxan]]
* [[F-15,599]]

== References ==
{{Reflist|30em}}

{{Analgesics}}
{{Antidepressants}}
{{Anxiolytics}}
{{Serotonergics}}

[[Category:Analgesics]]
[[Category:Pyridines]]
[[Category:Amines]]
[[Category:Organofluorides]]
[[Category:Piperidines]]
[[Category:Carboxamides]]
[[Category:Chloroarenes]]
[[Category:Fluoroarenes]]